Pharmacological Demonstration of the Additive Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism in Sodium Depleted Healthy Subjects

References

• Lees K. R. The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens. 1992; 10(suppl 5)S3–S11
   Google Scholar
• Meredith P. A., Donnelly R., Elliott H. L., Howie C. A., Reid J. L. Prediction of the antihypertensive response to enalapril. J Hypertens. 1990; 8: 1085–1090
   PubMed Web of Science ®Google Scholar
• Juillerat L., Nussberger J., Ménard J., Mooser V., Christen Y., Waeber B., Graf P., Brunner H. R. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16: 564–572
   PubMed Web of Science ®Google Scholar
• Van Den Meiracker A. H., Man in't veld A. J., Admiraal P. J.J., Ritsema Van Eck H. J., Boomsma F., Derkx F. H.M., Schalekamp M. A.D.H. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?. J Hypertens 1992; 10: 803–812
   PubMed Web of Science ®Google Scholar
• Urata H., Healy B., Stewart R. W., Bumpus F. M., Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990; 66: 883–890
   PubMed Web of Science ®Google Scholar
• Azizi M., Chatellier G., Guyene T. T., Murieta-Geoffroy D., Ménard J. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825–834
   PubMed Web of Science ®Google Scholar
• Azizi M., Guyene T. T., Chatellier G., Wargon M., Ménard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1996, (In press).
   Web of Science ®Google Scholar
• Weisser K., Schloos J., Lehmann K., Dusing R., Vetter H., Mutschler E. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol. 1991; 40: 95–99
   PubMed Web of Science ®Google Scholar
• Ohtawa M., Takayama F., Saitoh K., Yoshinaga T., Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993; 35: 290–297
   PubMed Web of Science ®Google Scholar
• Ménard J., Boger R. S., Moyse D. M., Guyene T. T., Glasmann H. N., Kleinert H. D. Dose-dependent effects of the renin inhibitor, zankiren HCL, after a single oral dose in mildly sodium depleted normotensive volunteers. Circulation 1995; 91: 330–338
   PubMed Web of Science ®Google Scholar
• McGregor G. A., Markandu N. D., Smith S. J., Sagnella G. A., Morton J. J. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981; 291: 329–331
   PubMed Web of Science ®Google Scholar
• Toffelmire E. B., Slater K., Corvol P., Ménard J., Schambelan M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal subjects. Studies using a direct immunoradiometric assay. J Clin Invest. 1989; 83: 679–687
   PubMed Web of Science ®Google Scholar
• Cirollo V. J., Gomez H. J., Salonen J., Salonen R., Rissanen V., Bolognese J. A., Nyberg R., Kristianson K. Lisinopril: dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol. 1988; 25: 533–538
   PubMed Web of Science ®Google Scholar
• Gradman A. H., Arcuri K. E., Goldberg A. I., Ikeda L. S., Nelson E. B., Snavely D. B., Sweet C. S. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345–1350
   PubMed Web of Science ®Google Scholar
• Guyene T. T., Bellet M., Sassano P., Serrurier D., Corvol P., Ménard J. Cross-over design for the dose determination of an angiotensin converting-enzyme inhibitor in hypertension. J Hypertens. 1989; 7: 1005–1012
   PubMed Web of Science ®Google Scholar
• Doig J. K., MacFadyen R. J., Sweet C. S., Lees K. R., Reid J. L. Dose-ranging study of the angiotensin type I receptor antagonist Losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993; 21: 732–738
   PubMed Web of Science ®Google Scholar
• Quinn S. J., Williams G. H. Regulation of aldosterone secretion. Ann Rev Physiol. 1988; 50: 409–426
   PubMed Web of Science ®Google Scholar
• Byyny R. L., Merrill D. M., Bradstreet T. E., Sweet C. S. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Cardiovasc Drug Therap. 1996, (In press).
   PubMed Web of Science ®Google Scholar
• Sadoshima J. U., Xu Y., Slayter H. S., Izumo S. Autocrine release of angiotensin II mediates strech-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993; 75: 977–984
   PubMed Web of Science ®Google Scholar
• Fernandez L. A., Caride V. J., Strömberg C., Nävery L., Wicke J. D. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol. 1994; 24: 937–940
   PubMed Web of Science ®Google Scholar
• Stoll M., Steckelings U. M., Paul M., Bottari S. P., Metzger R., Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995; 95: 651–657
   PubMed Web of Science ®Google Scholar
• Nakajima M., Hutchinson H. G., Fujinaga M., Hayashida W., Morishita R., Zhang L., Horiuchi M., Pratt R. E., Dzau V. S. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663–10667
   PubMed Web of Science ®Google Scholar
• Kerins D. M., Hao Q., Vaughan D. E. Angiotensin induction of PAI-1 expression in endothelial cells in mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995; 96: 2515–2520
   PubMed Web of Science ®Google Scholar
• Levy B. I., Benessiano J., Henrion D., Caputo L., Heymes C., Duriez M., Poitevin P., Samuel J. L. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest. 1996; 98: 418–425
   PubMed Web of Science ®Google Scholar
• Costerousse O., Allegrini J., Clozel J. P., Ménard J., Alhenc-Gelas F. Increased angiotensin-converting enzyme (ACE) gene expression during inhibitor treatment. Comparison with other blockers of the renin-angiotensin system. J Hypertens. 1994; 12(Suppl 3)S126
   Google Scholar